Sanofi-aventis and the Juvenile Diabetes Research Foundation (JDRF) are partnering to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease, as well as to prevent diabetes in those at risk.


Sanofi-aventis, Juvenile Diabetes Research Foundation, JDRF, diabetes, type 1 diabetes, type 2 diabetes, therapeutic treatments, Pierre Chancel, Jeffrey Brewer, insulin products, immune therapies, diabetes research


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Sanofi partners with Juvenile Diabetes Research Foundation

July 2nd, 2010

PARIS – Sanofi-aventis and the Juvenile Diabetes Research Foundation (JDRF) are partnering to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease, as well as to prevent diabetes in those at risk.

The pharmaceutical giant said Thursday that the treatments will be for both those living with the disease and the newly diagnosed. The partnership will focus on therapeutics such as immune therapies and beta cell regeneration.

Under the alliance, sanofi-aventis and JDRF will jointly provide academic investigators and nonprofit medical research organizations with funding to conduct research projects in regeneration and immune therapy. The partnership will provide sanofi-aventis with options to the intellectual property developed by researchers who receive funding through the program.

"Sanofi-aventis is committed to providing health care solutions that meet the needs of people with diabetes and their families," Pierre Chancel, senior vice president of global diabetes for sanofi-aventis, said in a statement. "Our long-acting insulin is one of the leading insulin products for patients with type 1 and type 2 diabetes, and we continue to invest in research for additional therapies and solutions to meet the unmet needs of patients. Our partnership with the Juvenile Diabetes Research Foundation is an opportunity to help fund innovative research that will improve therapies and perhaps even find a cure for type 1 diabetes."

Sanofi-aventis said the partnership will capitalize on the JDRF's network of academicians, institutions and biotech partners and leveraging sanofi-aventis' drug development experience to help bring products and technologies to the clinic — and eventually to patients.

"JDRF is focused on immune therapies and regeneration as two key areas to develop better treatments and cures for diabetes," stated Jeffrey Brewer, president and chief executive officer of JDRF. "Partnering with businesses such as sanofi-aventis, with their tremendous experience in bringing research to market to benefit patients, is an important way we can accelerate the pace of science leading to a cure."

JDRF is the largest charitable funder of diabetes research in the world, funding more than $1.4 billion since its inception, including more than $107 million worldwide in the last year.

Sanofi-aventis reported that worldwide in 2008 there were an estimated 246 million people with diabetes, and the World Health Organisation expects that figure to rise to 370 million by 2030.

Advertisement